Soluble or soluble/membrane TNF-± inhibitors protect the brain from focal ischemic injury in rats
Tumor Necrosis Factor-alpha (TNF-α) is an immunomodulatory and proinflammatory cytokine implicated in neuro-inflammation and neuronal damage in response to cerebral ischemia. The present study tested the hypothesis that anti-TNF-α agents may be protective against cerebral infarction. Transient focal...
- Autores:
-
Arango Dávila, César Augusto
Cardozo, Carlos F.
Londoño, Ana C.
Cañas, Carlos A.
Rengifo, Juliana
Orozco, Jorge Luis
Cañas, Felipe
Echeverri, Andrés F.
Vera, Alejandro
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2015
- Institución:
- Universidad ICESI
- Repositorio:
- Repositorio ICESI
- Idioma:
- eng
- OAI Identifier:
- oai:repository.icesi.edu.co:10906/82290
- Acceso en línea:
- http://www.tandfonline.com/doi/full/10.3109/00207454.2014.980906
http://hdl.handle.net/10906/82290
http://dx.doi.org/10.3109/00207454.2014.980906
- Palabra clave:
- Ratas - Experimentos
Isquemia cerebral
Cerebro
Anticuerpos monoclonales
Infarto cerebral
Ciencias socio biomédicas
Biomedical sciences
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by-nc-nd/4.0/
| Summary: | Tumor Necrosis Factor-alpha (TNF-α) is an immunomodulatory and proinflammatory cytokine implicated in neuro-inflammation and neuronal damage in response to cerebral ischemia. The present study tested the hypothesis that anti-TNF-α agents may be protective against cerebral infarction. Transient focal ischemia was artificially induced in anesthetized adult male Wistar rats (300–350 g) by middle cerebral artery occlusion (MCAO) with an intraluminal suture. TNF-α function was interfered with either a chimeric monoclonal antibody against TNF-α (infliximab-7 mg/kg) aiming to TNF-α soluble and membrane-attached form; or a chimeric fusion protein of TNF-α receptor-2 with a fragment crystallizable (Fc) region of IgG1 (etanercept-5 mg/kg) aiming for the TNF-α soluble form. Both agents were administered intraperitoneally 0 or 6 h after inducing ischemia. Infarct volume was measured by 2,3,5-triphenyltetrazolium chloride staining. Cerebral infarct volume was significantly reduced in either etanercept or infliximab-treated group compared with non-treated MCAO rats 24 h after reperfusion. These results suggest that anti-TNF-α agents may reduce focal ischemic injury in rats. |
|---|